J. Fernando Arevalo, MD, FACS, shares findings from his presentation on using brolucizumab to treat neovascular AMD, and whether the novel therapy is better than current treatment.
Key takeaways from the RGX-314 (Regenxbio) phase I/IIa clinical trial indicate that the novel gene therapy is a promising approach for treating wet AMD, noted Jeffrey Heier, MD.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
